ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO750

Clinical Study Results of a Real-Time Point-of-Care Glomerular Filtration Rate Measurement

Session Information

Category: Glomerular

  • 1004 Clinical/Diagnostic Renal Pathology and Lab Medicine


  • Dorshow, Richard B., MediBeacon Inc., Saint Louis, Missouri, United States
  • Debreczeny, Martin, MediBeacon Inc., St Louis, Missouri, United States
  • Johnson, James R., MediBeacon Inc., St Louis, Missouri, United States
  • Shieh, jeng-jong, MediBeacon Inc., St Louis, Missouri, United States
  • Rogers, Thomas E, MediBeacon Inc, St Louis, Missouri, United States
  • Martin, Kevin J., Saint Louis University Med Ctr, St. Louis, Missouri, United States
  • Coyne, Daniel W., Washington University School of Medicine, St. Louis, Missouri, United States

Real-time point-of-care measure of glomerular filtration rate (mGFR) would permit rapid diagnosis of acute kidney injury and precise determination of CKD. Clearance pharmacokinetics of the fluorescent agent MB-102 was measured in the plasma and correlated with noninvasively measured transdermal fluorescence for subjects with normal kidney function to Stage 4 CKD.


Blood samples were taken in 60 subjects with eGFR from normal to 19 mL/min/1.73m2 over a period of 12hr post simultaneous administration of MB-102 and iohexol, and urine collected to assess percent excretion. A noninvasive detection device simultaneously measured the transdermal fluorescence from MB-102.


Plasma pharmacokinetics displayed the expected 2 compartment model of a vascular-tissue equilibrium phase followed by renal excretion only. The GFR measured from the MB-102 plasma pharmacokinetics was highly correlated with the GFR measured from iohexol over the entire measured range of GFR values (r2=0.98). The time-dependence of the transdermal fluorescence from MB-102 monitored by our fluorescence detection device was highly correlated with that of the plasma (see figure from subject with normal mGFR). MB-102 was completely cleared by 12hr when mGFR was >60 mL/min/1.73m2. No serious nor significant adverse events were reported.


Point-of-care clinically amenable measured GFR for a range of kidney function from normal to Stage 4 CKD is demonstrated using transdermal fluorescence detection of the novel fluorescence tracer agent MB-102.


  • Commercial Support